Agile Therapeutics Inc

NASDAQ:AGRX  
1.48
-0.04 (-2.63%)
Other Pre-Announcement

Agile Therapeutics- Reaffirmed Its Previously Announced Operating Expense Guidance For Full Year 2020 To Be In Range Of $52 Mln To $56 Mln

Published: 09/21/2020 21:08 GMT
Agile Therapeutics Inc (AGRX) - Agile Therapeutics Inc - Reaffirmed Its Previously Announced Operating Expense Guidance for Full Year 2020 to Be in Range of $52 Million to $56 Million.
Agile Therapeutics Inc - Reaffirmed Its Previously Announced Net Revenue Guidance for Q4 of 2020 to Be in Range of $1 Million to $2 Million.
Agile Therapeutics - Cash, Cash Equivalents and Marketable Securities As of June 30, 2020 Will Be Sufficient Through End of 2021.